抗膜抗体至少持续一年，并能区分过去的 2019 年冠状病毒病感染和疫苗接种。
Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination.
机构信息
Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
出版信息
J Infect Dis. 2022 Nov 28;226(11):1897-1902. doi: 10.1093/infdis/jiac263.
Abstract
BACKGROUND
The consequences of past coronavirus disease 2019 (COVID-19) infection for personal and population health are emerging, but accurately identifying distant infection is a challenge. Anti-spike antibodies rise after both vaccination and infection and anti-nucleocapsid antibodies rapidly decline.
METHODS
We evaluated anti-membrane antibodies in COVID-19 naive, vaccinated, and convalescent subjects to determine if they persist and accurately detect distant infection.
RESULTS
We found that anti-membrane antibodies persist for at least 1 year and are a sensitive and specific marker of past COVID-19 infection.
CONCLUSIONS
Thus, anti-membrane and anti-spike antibodies together can differentiate between COVID-19 convalescent, vaccinated, and naive states to advance public health and research.
摘要
背景
过去的 2019 冠状病毒病（COVID-19）感染对个人和人群健康的后果正在显现，但准确识别远期感染是一项挑战。接种疫苗和感染后都会产生针对刺突蛋白的抗体，而核衣壳蛋白的抗体则迅速下降。
方法
我们评估了 COVID-19 初治、接种疫苗和康复受试者的抗膜抗体，以确定它们是否持续存在并准确检测远期感染。
结果
我们发现抗膜抗体至少持续 1 年，是过去 COVID-19 感染的敏感和特异性标志物。
结论
因此，抗膜和抗刺突抗体一起可以区分 COVID-19 康复、接种疫苗和初治状态，以推进公共卫生和研究。
相似文献
1
Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination.抗膜抗体至少持续一年，并能区分过去的 2019 年冠状病毒病感染和疫苗接种。
J Infect Dis. 2022 Nov 28;226(11):1897-1902. doi: 10.1093/infdis/jiac263.
2
Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination.抗膜抗体和抗刺突抗体具有持久性，二者共同可区分既往新冠病毒感染和疫苗接种情况。
medRxiv. 2021 Nov 8:2021.11.02.21265750. doi: 10.1101/2021.11.02.21265750.
3
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.新冠病毒感染 14 个月后 COVID-19 恢复期患者结合抗体和中和抗体的动态分析。
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
4
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.比较 BNT162b2 mRNA 疫苗接种者的恢复期和未接种者的 SARS-CoV-2 抗刺突蛋白 RBD IgG 和中和抗体与 COVID-19 患者的动力学。
BMC Med. 2021 Aug 23;19(1):208. doi: 10.1186/s12916-021-02090-6.
5
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应，发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
6
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?核蛋白血清学阳性用于检测轻度和无症状的 SARS-CoV-2 感染：COVID-19 疫苗接种后突破感染的检测补充工具？
Vaccine. 2022 Apr 1;40(15):2251-2257. doi: 10.1016/j.vaccine.2022.03.009. Epub 2022 Mar 9.
7
Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination.先前的 SARS-CoV-2 感染增强并重塑了疫苗接种诱导的刺突蛋白特异性记忆。
Sci Transl Med. 2023 Mar 15;15(687):eade0550. doi: 10.1126/scitranslmed.ade0550.
8
SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study.接种疫苗的克罗地亚医护人员和感染住院患者的 SARS-CoV-2 刺突蛋白和核衣壳抗体反应：一项单中心队列研究。
Viruses. 2022 Sep 4;14(9):1966. doi: 10.3390/v14091966.
9
SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.SARS-CoV-2 抗体检测在医护人员中的应用：三种市售抗体检测试剂盒的临床性能比较。
Microbiol Spectr. 2021 Oct 31;9(2):e0039121. doi: 10.1128/Spectrum.00391-21. Epub 2021 Sep 29.
10
Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.新型冠状病毒病患者中严重急性呼吸综合征冠状病毒 2 核衣壳蛋白和刺突蛋白抗体检测的敏感性。
J Infect Dis. 2020 Jun 29;222(2):206-213. doi: 10.1093/infdis/jiaa273.
引用本文的文献
1
Case Report: Two episodes of hyperinflammation in an infant consistent with multisystem inflammatory syndrome in children: recurrence or rather two different diseases?病例报告：一名婴儿出现两期与儿童多系统炎症综合征相符的高度炎症：复发还是两种不同的疾病？
Front Pediatr. 2025 Jun 5;13:1559244. doi: 10.3389/fped.2025.1559244. eCollection 2025.
2
Rheumatoid arthritis-associated rheumatoid factors post-COVID-19.新冠病毒感染后类风湿关节炎相关的类风湿因子
Front Immunol. 2025 Feb 13;16:1553540. doi: 10.3389/fimmu.2025.1553540. eCollection 2025.
3
Quantitative IgG response to SARS-CoV-2 membrane protein in infected individuals strongly correlates with lung injury.感染个体对新冠病毒膜蛋白的定量IgG反应与肺损伤密切相关。
Sci Rep. 2024 Dec 28;14(1):30665. doi: 10.1038/s41598-024-78381-8.
4
Limited Biomarker Potential for IgG Autoantibodies Reactive to Linear Epitopes in Systemic Lupus Erythematosus or Spondyloarthropathy.系统性红斑狼疮或脊柱关节炎中对线性表位有反应的IgG自身抗体的生物标志物潜力有限。
Antibodies (Basel). 2024 Oct 12;13(4):87. doi: 10.3390/antib13040087.
5
Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques.VLA2001疫苗对雄性食蟹猴感染严重急性呼吸综合征冠状病毒2的免疫原性和有效性
Commun Med (Lond). 2024 Apr 3;4(1):62. doi: 10.1038/s43856-024-00488-w.
6
Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein.研究 SARS-CoV-2 个体蛋白揭示了膜蛋白的体外和体内免疫原性。
Sci Rep. 2023 Dec 18;13(1):22873. doi: 10.1038/s41598-023-49077-2.
7
Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 Months.美国一大群人在12个月期间的新冠病毒血清流行率动态
medRxiv. 2023 Oct 21:2023.10.20.23297329. doi: 10.1101/2023.10.20.23297329.
8
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.通过高内涵显微镜技术将严重急性呼吸综合征冠状病毒2（SARS-CoV-2）膜蛋白特异性抗体确立为有价值的血清学靶点。
iScience. 2023 Jul 21;26(7):107056. doi: 10.1016/j.isci.2023.107056. Epub 2023 Jun 7.
9
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.分析不同接种和未接种康复期血浆来源中针对 SARS-CoV-2 奥密克戎的中和抗体效价。
Nat Commun. 2022 Oct 29;13(1):6478. doi: 10.1038/s41467-022-33864-y.
10
Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors.使用无标记纳米等离子体生物传感器对人血清中的新冠病毒抗体进行多重定量分析。
Biomed Opt Express. 2022 Mar 16;13(4):2130-2143. doi: 10.1364/BOE.454919. eCollection 2022 Apr 1.
Zotero 插件